Does Your Child Have a Peanut Allergy? Learn about a Treatment Option


Peanut allergy is the most common food allergy in children in the U.S. and affects approximately 1.3 million children between the ages of 4 – 17.1

If your child has a peanut allergy, you know firsthand the burden it can have on your family. It can be a life-long condition, and reactions to peanuts can range from mild to potentially life-threatening.

Exposure to even a small amount of allergen can prompt an allergic reaction2; approximately one in five children with physician-diagnosed peanut allergy had at least one peanut-allergy related emergency department visit in a single year within the U.S.3

Practicing a strict peanut-free diet alone may not be enough. No matter how careful you are as a parent, a family, or a community, accidental exposure can still happen anytime, anywhere, and the constant vigilance can be exhausting. As a result, peanut allergy is associated with a burden that impacts patients and their families daily, as they struggle to avoid accidental exposure and a potentially life-threatening reaction.4 Until last year, there was no FDA-approved treatment option available for peanut allergy.

In January 2020, the U.S. Food and Drug Administration (FDA) approved PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA can help your child gradually decrease their sensitivity to peanuts over time through a process called oral immunotherapy, or OIT.


PALFORZIA is a treatment for people who are allergic to peanuts. PALFORZIA can help reduce the severity of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. PALFORZIA may be started in patients aged 4 through 17 years old. If you turn 18 years of age while on PALFORZIA treatment you should continue taking PALFORZIA unless otherwise instructed by your doctor.

PALFORZIA does NOT treat allergic reactions and should not be given during an allergic reaction.

You must maintain a strict peanut-free diet while taking PALFORZIA.


PALFORZIA can cause severe allergic reactions called anaphylaxis that may be life-threatening.

  • You will receive your first dose in a healthcare setting under the observation of trained healthcare staff.
  • You will receive the first dose of all dose increases in a healthcare setting.
  • In the healthcare setting, you will be observed for at least 1 hour for signs and symptoms of a severe allergic reaction.
  • If you have a severe reaction during treatment, you will need to receive an injection of epinephrine immediately and get emergency medical help right away.
  • You will return to the healthcare setting for any trouble tolerating your home doses.

Stop taking PALFORZIA and get emergency medical treatment right away if you have any of the following symptoms after taking PALFORZIA:

  • Trouble breathing or wheezing
  • Chest discomfort or tightness
  • Throat tightness
  • Trouble swallowing or speaking
  • Swelling of your face, lips, eyes, or tongue
  • Dizziness or fainting
  • Severe stomach cramps or pain, vomiting, or diarrhea
  • Hives (itchy, raised bumps on skin)
  • Severe flushing of the skin

Because of the risk of severe allergic reactions, PALFORZIA is only available through a restricted program called the PALFORZIA Risk Evaluation and Mitigation Strategy (REMS) Program. Talk to your healthcare provider for more information about the PALFORZIA REMS program and how to enroll.

You should NOT take PALFORZIA if you have uncontrolled asthma, or if you ever had eosinophilic esophagitis (EoE) or other eosinophilic gastrointestinal disease.

Tell your doctor if you are not feeling well prior to starting treatment with PALFORZIA. Your doctor may decide to delay treatment until you are feeling better. Also tell your doctor about any medical conditions you have and if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal supplements.

Your doctor may decide that PALFORZIA is not the best treatment if:

  • You are unwilling or unable to receive (or self-administer) injectable epinephrine.
  • You have a condition or are taking a medication that reduces the ability to survive a severe allergic reaction.

What are the possible side effects of PALFORZIA?

The most commonly reported side effects of PALFORZIA were: stomach pain, vomiting, feeling sick, itching or burning in the mouth, throat irritation, cough, runny nose, sneezing, throat tightness, wheezing, shortness of breath, itchy skin, hives, and/or itchy ears.

PALFORZIA can cause severe allergic reactions called anaphylaxis that may be life-threatening.

PALFORZIA can cause stomach or gut symptoms including inflammation of the esophagus (called eosinophilic esophagitis). Symptoms of eosinophilic esophagitis can include:

  • Trouble swallowing
  • Food stuck in throat
  • Burning in chest, mouth, or throat
  • Vomiting
  • Regurgitation of undigested food
  • Feeling sick

For additional information on the possible side effects of PALFORZIA, talk with your doctor or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1.800.FDA.1088. Please see full Prescribing Information and Medication Guide, including an Important Warning about anaphylaxis.

Starting Small

At your child’s first treatment appointment, your allergist will start by administering small, increasing doses of PALFORZIA. If these doses are tolerated, your child can continue on to the next step in the treatment pathway.

Decreasing Sensitivity Over Time

You will return to the allergist’s office the next day, so your child can begin the Up-Dosing phase of treatment. Your allergist will administer the first dose of PALFORZIA and monitor carefully to make sure your child can keep taking PALFORZIA.

Starting on the next day, you will give your child the same dose of PALFORZIA every day at home, mixed into a small amount of soft food, until it is time to visit the allergist again (about 2 weeks later) to see if your child is ready for the next, higher dose. It will take at least six months to make it through all the Up-Dosing levels.


1 Mahr et al. Characteristics of Peanut Allergy Diagnosis in a US Health Care Claims Database (2011-2017). J Allergy Clin Immunol Pract. 2021 Apr;9(4):1683-1694.
2 Deschildre A, Elegbédé CF, Just J, Bruyère O, et al. Peanut-allergic patients in the MIRABEL survey: characteristics, allergists’ dietary advice and lessons from real life. Clin Exp Allergy. 2016;46(4):610-620.
3 Gupta R, Warren C, Smith B, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018;142:e20181235.
4 DunnGalvin A, Blumchen K, Timmermans F, et al. APPEAL-1: A multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020;75(11):2899-2908.


Comments are closed.